ReviewClinical cardiology2012
Cannabinoids and atherosclerotic coronary heart disease.
Review in Clinical cardiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Associations Between Marijuana Use and Cardiovascular Risk Factors and Outcomes: A Systematic Review.Annals of internal medicine · 2018Pooled it
- Single-Cell Analysis, Spatial Transcriptomics and Molecular Docking Unveil Potential Therapeutic Targets for Carotid Atherosclerosis.Balkan medical journal · 2026Article
- Article
- Lifetime Cannabis Use and Incident Hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.Hypertension (Dallas, Tex. : 1979) · 2025Observational
- Association of Smoking Cannabis With Cardiovascular Events Among Veterans With Coronary Artery Disease.Circulation · 2025Article
- Recurrent Peripheral Artery Disease in a 45-Year-Old Male Without Hypercoagulable Comorbidities.Cureus · 2025Article
- Quantifying Heart Rate Changes After Delta-9-Tetrahydrocannabinol Administration Using a PBPK-PD Model in Healthy Adults.Pharmaceutics · 2025Article
- Regular cannabis smoking and carotid artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).Vascular medicine (London, England) · 2024Article
- Article
- Design, Synthesis, and Characterization of Novel Cannabidiol-Based Derivatives with Potent Antioxidant Activities.International journal of molecular sciences · 2024Article
- Phytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer's Disease.Current drug research reviews · 2024Review
- Evaluation of the cardiovascular risk induced by cannabis use from a series of 43 autopsy cases.International journal of legal medicine · 2023Observational
- Cannabinoids in the Modulation of Oxidative Signaling.International journal of molecular sciences · 2023Review
- The Endocannabinoid System and Physical Exercise.International journal of molecular sciences · 2023Review
- There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.American journal of preventive cardiology · 2022Review
- Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone.Acta pharmacologica Sinica · 2022Article
- Adverse Effects of Cannabinoids and Tobacco Consumption on the Cardiovascular System: A Systematic Review.Cureus · 2022Review
- Thrombosis within the left anterior descending coronary artery and left ventricle after high-dose nitrous oxide use.BMJ case reports · 2022Article
- Relation of Cannabis Use to Elevated Atherosclerotic Cardiovascular Disease Risk Score.The American journal of cardiology · 2022Article
- Cardiac Transplantation and the Use of Cannabis.Life (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marijuana is the most abused recreational drug in the United States. Cannabinoids, the active ingredients of marijuana, affect multiple organ systems in the human body. The pharmacologic effects of marijuana, based on stimulation of cannabinoid receptors CB1 and CB2, which are widely distributed in the cardiovascular system, have been well described. Activation of these receptors modulates the function of various cellular elements of the vessel wall, and may contribute to the pathogenesis of atherosclerosis. Clinically, there are reports linking marijuana smoking to the precipitation of angina and acute coronary syndromes. Recently, large published clinical trials with CB1 antagonist rimonabant did not show any significant benefit of this agent in preventing progression of atherosclerosis. In light of these findings and emerging data on multiple pathways linking cannabinoids to atherosclerosis, we discuss the literature on the role of cannabinoids in the pathophysiology of atherosclerosis. We also propose a marijuana paradox, which implies that inhalation of marijuana may be linked to precipitation of acute coronary syndromes, but modulation of the endocannabinoid system by a noninhalation route may have a salutary effect on the development of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.